Lonza's Midterm Targets Support Growth Outlook, But Alone Won't Lift Consensus -- Market Talk
Lonza's Midterm Targets Support Growth Outlook, But Alone Won't Lift Consensus -- Market Talk
0937 GMT - Lonza's latest mid-term targets ahead of its capital markets day bode well for the Swiss biotech and chemical company's growth outlook, even if consensus expectations are likely to already have caught up, UBS says. But the update, including a core Ebitda margin of 33%-35% and double-digit growth, is being pushed out to 2024 from 2023, which could imply that margin expansion will be slower than previously thought, the bank says. The forecasts are unlikely to result in material changes to consensus, however, and so the tone of management at the CMD will prove more important to where the shares will head in response, the bank says. UBS maintains a neutral rating. Shares rise 1.3% to CHF703.80. (edward.frankl@dowjones.com)
0937GMT-瑞銀(UBS)表示，龍沙在資本市場日之前的最新中期目標對這家瑞士生物技術和化工公司的增長前景來説是個好兆頭，儘管共識預期可能已經趕上。但該行表示，最新數據包括核心EBITDA利潤率為33%-35%，以及兩位數的增長，將從2023年推遲到2024年，這可能意味着利潤率的增長將比之前預期的要慢。然而，該行表示，這些預測不太可能導致共識發生實質性變化，因此CMD管理層的基調將被證明對股價將走向何方更為重要。瑞銀維持中性評級。股價上漲1.3%，至703.80瑞士法郎。(edward.frkl@dowjones.com)
譯文內容由第三人軟體翻譯。